France is planning to slow down its vaccine rollout after its hospital staff were unable to work due to numerous side-effects from the COVID-19 vaccine. Hospitals in different parts of the country are facing shortage of staff too because half of the workers are on sick leave after getting vaccinated.
The AstraZeneca experimental COVID-19 vaccine is being given to many health workers. People who got vaccinated for COVID-19 in France had to face numerous side effects.
French vaccination task force is considering slowing vaccine rollout for people working in the same unit.
Health workers have been facing side effects like headache, sore muscles and high fever.
They had to stop work because of these symptoms. Many incidents have been registered in many hospitals in the country where workers got vaccinated.
Subscribe to GreatGameIndia
Many hospitals are already facing shortage of COVID-19 units and ICUs and now these hospitals in different parts of the country are facing shortage of staff too because half of the workers are on sick leave after getting vaccinated.
They are facing the same situations since the inception of the vaccine campaign.
AstraZeneca pharmaceutical company and Oxford University, had developed this vaccine by cultivating weekend SARS-CoV-2 virus in the HEK-293 cell line. It was derived from the kidney of an aborted baby.
Oxford Vaccine Centre claimed that these virus cultures “are purified several times to remove the cell culture material,” adding that “this makes it unlikely that any human material remains in the final vaccine.”
Started on 5th Feb, this campaign could not receive the positive response during the first week.
The university hospital of Brest in Brittany had to face issues as 15 to 25% workers who got vaccinated had to face side effects and stop work. The authorities of hospitals had to take the decision to stop vaccination.
Other hospitals in Brittany had also gone through the same situation. More than 20% of health workers were on leave after having a vaccine.
On Feb 11th, the hospital of Saint-Lô had to stop vaccination as 10 out of 50 workers had experienced side effects after receiving the vaccine. They suffered from side effects like nausea, fever and other symptoms.
Till date, 149 “pharmacovigilance declarations” had been filed and 10,000 shots had been delivered to people working in the healthcare sector.
Hospital workers do not want to get vaccinated in the Dordogne as per the local media. The “Hygiene and Security Committee” of the hospital reported 40 to 70 percent people experiencing heavy side effects after getting vaccinated.
Till 16th Feb 2021, approximately 363 adverse events have been reported among the healthcare workers who recently got vaccinated.
On average the age group of these healthcare is from 31 to 50 years of age. In most of the adverse event cases, the recipients of the vaccine suffered from high intensity “pseudo-influenza syndromes”.
The efficacy rate of this vaccine is just 62-70%. Also, the vaccine is causing highly serious symptoms as compared to COVID-19 infection within the people of the age group of 30-50 years.
Also, it is not clear whether AstraZeneca jab is actually effective in curbing the COVID-19 infection as the virus was detected in people who were vaccinated during the trials.
Surprisingly, France appears to be the only European country where this vaccine is causing such serious side effects.
“The older a person is, the slower the immune system’s response to the vaccine, so by default, older people develop fewer side effects from the vaccine because their immune system reacts too weakly,” explained Eric Billy.
Inversely, he said, younger people have a “very reactive immune system, and it’s rather reassuring that there are these kinds of side effects, it shows that there is an immune response.”
The question that he did not answer is the one regarding the giving of vaccines to people over 75 with weakened immune systems. Is this useful? Can it be dangerous?
Meanwhile, numerous European countries have decided not to use AstraZeneca COVID-19 vaccine for people over 65.
This decision was made due to the lack of data available about its effectiveness in elderly people.
For latest updates on the outbreak check out our Coronavirus Coverage.